Retrieve available abstracts of 17 articles: HTML format
Single Articles
May 2025
KOELE SE, Heinrich N, De Jager VR, Dreisbach J, et al Population pharmacokinetics and exposure-response relationship of the
antituberculosis drug BTZ-043.
J Antimicrob Chemother. 2025;80:1315-1323. PubMedAbstract available
April 2025
METARFI Y, Chellal W, Ben Khadda Z, Hoummani H, et al Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review.
J Antimicrob Chemother. 2025 Apr 21:dkaf126. doi: 10.1093. PubMedAbstract available
KANG SW, Jang HM, Chang E, Bae S, et al Impact of fluoroquinolone exposure on the diagnosis and prognosis of tuberculosis
in immunocompromised patients: a propensity-score-matched, competing risk
analysis.
J Antimicrob Chemother. 2025 Apr 7:dkaf111. doi: 10.1093. PubMedAbstract available
February 2025
LIU W, Xu N, Li W, Mak WY, et al Pharmacokinetics and safety of rifapentine in children: dosing for latent
tuberculosis infection.
J Antimicrob Chemother. 2025 Feb 13:dkaf029. doi: 10.1093. PubMedAbstract available
January 2025
CHEN S, Shang Y, Zheng J, Huo F, et al In vitro monitoring of drug resistance emergence during stepwise induction of
bedaquiline and clofazimine, alone and in combination: a phenotypic and genotypic
analysis.
J Antimicrob Chemother. 2025;80:262-269. PubMedAbstract available
December 2024
LI X, Qi X, Wang B, Fu L, et al Efficacy of nintedanib as a host-directed therapy candidate in the treatment of
tuberculosis.
J Antimicrob Chemother. 2024 Dec 4:dkae429. doi: 10.1093. PubMedAbstract available
November 2024
AGIBOTHU KUPPARAM HK, Shah I, Chandrasekaran P, Mane S, et al Pharmacokinetics of anti-TB drugs in children and adolescents with drug-resistant
TB: a multicentre observational study from India.
J Antimicrob Chemother. 2024;79:2939-2947. PubMedAbstract available
October 2024
LIN YJ, Zou Y, Karlsson MO, Svensson EM, et al A pharmacometric multistate model for predicting long-term treatment outcomes of
patients with pulmonary TB.
J Antimicrob Chemother. 2024;79:2561-2569. PubMedAbstract available
August 2024
WALTER K, Te Brake LHM, Lemm AK, Hoelscher M, et al Investigating the treatment shortening potential of a combination of bedaquiline,
delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis
model with confirmed drug exposures.
J Antimicrob Chemother. 2024 Aug 7:dkae266. doi: 10.1093. PubMedAbstract available
WIJK M, Gausi K, Malatesta S, Weber SE, et al The impact of alcohol and illicit substance use on the pharmacokinetics of
first-line TB drugs.
J Antimicrob Chemother. 2024;79:2022-2030. PubMedAbstract available
June 2024
KARAKITSIOS E, Dokoumetzidis A Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical
species to humans using PBPK modelling.
J Antimicrob Chemother. 2024;79:1362-1371. PubMedAbstract available
April 2024
PHAISAL W, Albitar O, Chariyavilaskul P, Jantarabenjakul W, et al Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in
paediatrics with tuberculosis infection.
J Antimicrob Chemother. 2024 Apr 25:dkae059. doi: 10.1093. PubMedAbstract available
STEMKENS R, Mouhdad C, Franssen EJF, Touw D, et al Ten-year results of an international external quality control programme for
measurement of anti-tuberculosis drug concentrations.
J Antimicrob Chemother. 2024 Apr 6:dkae105. doi: 10.1093. PubMedAbstract available
VAN INGEN J Why do we use 100 mg of clofazimine in TB and NTM treatment?
J Antimicrob Chemother. 2024;79:697-702. PubMedAbstract available
March 2024
YUNIVITA V, Gafar F, Santoso P, Chaidir L, et al Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of
rifampicin- or multidrug-resistant tuberculosis in Indonesia.
J Antimicrob Chemother. 2024 Mar 9:dkae057. doi: 10.1093. PubMedAbstract available
December 2023
COMBRINCK J, Tshavhungwe P, Rohlwink U, Enslin N, et al Rifampicin and protein concentrations in paired spinal versus ventricular
cerebrospinal fluid samples of children with tuberculous meningitis.
J Antimicrob Chemother. 2023 Dec 15:dkad371. doi: 10.1093. PubMedAbstract available
September 2023
MOK S, Roycroft E, Flanagan PR, Wagener J, et al Investigation of genomic mutations and their association with phenotypic
resistance to new and repurposed drugs in Mycobacterium tuberculosis complex
clinical isolates.
J Antimicrob Chemother. 2023 Sep 23:dkad252. doi: 10.1093. PubMedAbstract available